Information
ATLANTA, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ:AQST) complied with federal securities laws. On January
Original sourceAI Summary
Holzer & Holzer is investigating Aquestive's compliance with federal laws. FDA identified deficiencies in AQST's NDA for Anaphylm sublingual film. The stock price dropped significantly following this news.
Sentiment Rationale
Historical cases, like that of Valeant Pharmaceuticals, show regulatory issues can severely affect stock value. AQST's current challenges raise doubt about its market viability.
Trading Thesis
The immediate effect of the FDA's findings and the investigation could alter investor sentiment quickly. Legal resolutions, or lack thereof, might influence AQST’s performance in the near term.
Market-Moving
- FDA deficiencies in AQST's NDA could delay product launch.
- Legal investigations can overshadow AQST's performance for investors.
- Stock drop indicates significant market sentiment against AQST.
- Increased scrutiny might lead to further legal ramifications for AQST.
Key Facts
- Holzer & Holzer is investigating Aquestive's compliance with federal laws.
- FDA identified deficiencies in AQST's NDA for Anaphylm sublingual film.
- The stock price dropped significantly following this news.
Companies Mentioned
- SPPI (SPPI)
- AMRN (AMRN)
Legal
The developments involve potential legal and regulatory consequences that are critical to AQST's operational integrity and stock value.
ATLANTA, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ:AQST) complied with federal securities laws. On January 9, 2026, Aquestive disclosed that it received a notice from the FDA that it "had identified deficiencies in the New Drug Application (NDA) submitted by the Company for its product candidate, Anaphylm™ (epinephrine) Sublingual Film, for the treatment of severe allergic reactions, including anaphylaxis, that preclude discussion of labeling and post-marketing commitments for Anaphylm." Following this news, the price of the Company's stock dropped.
If you purchased Aquestive stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/aquestive-therapeutics/ to discuss your legal rights.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
